IFPMA names new Communications Director

Published on: 01 November 2017

Appointment Release

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) names new Communications Director

 

Geneva, 1st November 2017 – IFPMA, the global research-based biopharmaceutical industry association, has today appointed Helen Gallagher as its new Communications Director. She will act as a key spokesperson for the organization in its interaction with stakeholders in Geneva and the wider global health community.
“I am delighted to welcome Helen in the team. She will be instrumental in articulating our value proposition, building partnerships and alliances, and representing our industry in discussions with permanent missions to the United Nations, intergovernmental organizations, and other non-governmental organizations, foundations, and academic institutions”, said Thomas Cueni, IFPMA Director General.
Ms. Gallagher has more than 20 years’ experience in health and biopharmaceutical communications in both leading consultancy and global industry roles. She also shaped and led corporate responsibility and advocacy programmes and was subsequently recognized in such key roles.
Commenting on her new role she said “I am joining IFPMA at an exciting time. I look forward to getting the message out there of the many contributions that the R&D-based biopharmaceutical industry has made, and will make, to improve public health and to enable governments to meet ambitious goals such as universal health coverage (UHC), global health security and continued innovation in areas of high unmet health needs such as antimicrobial resistance (AMR). I look forward to working with the IFPMA team to help strengthen the industry voice, build bridges among diverse global health actors, champion solutions, and demonstrate that we are an essential partner in resolving health problems globally”.
Prior to taking up her new role at IFPMA, Ms. Gallagher headed up for over twelve years the Corporate Communications position at Ferring Pharmaceuticals, a global biopharmaceutical company specializing in innovative peptide and hormone treatments and with a particular focus on reproductive and maternal health. She was also responsible for the Ferring Corporate Social Responsibility program and led its CSR taskforce. Previously, she held healthcare director positions at Manning Selvage & Lee, Cohn & Wolfe, and The Rowland Company as well as Media Relations Manager and international spokesperson for Ciba Specialty Chemicals.
In addition to her native English, Ms. Gallagher speaks French and German.

Ms. Gallagher is reachable via mail h.gallahger@ifpma.org and phone +41 22 338 32 19.

About IFPMA
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

For further information, please contact:
Sadia Kaenzig | Communications Manager | s.kaenzig@ifpma.org | +41 22 338 32 49
Morgane De Pol | Manager, Communications and Public Affairs | m.depol@ifpma.org +41 22 338 32 00


ABOUT IFPMA

IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

MEDIA ENQUIRIES

Morgane De Pol
Manager, Communications and Public Affairs
+41 22 338 32 00

Sadia Kaenzig
Manager, Communications
+41 22 338 32 00

Tags